SBI's strong international investor base includes some of the largest leading institutional investors in North America, Asia and Europe. The company obtains its principal revenues from target-specific drug discovery collaborations with international pharmaceutical companies. Additional revenues are the result of subscriptions to its proprietary structural bioinformatics database, ProMax™, and subscriptions to its proprietary series of variant protein databases, Variome™. Sales of individual protein structures to pharmaceutical and biotechnology companies provide genomics-derived structural information in a seamless interface with structure-based drug discovery and structure-focused ultra-high throughput computational (pre)screening of compound libraries and virtualized combinatorial libraries.